Skip to main content
. 2021 Sep 1;156(10):1–10. doi: 10.1001/jamasurg.2021.3182

Table 1. Patient Demographic and Tumor Characteristics (Modified Intention-to-Treat Population).

Variable LG (n = 119) RG (n = 117)
Patient demographic characteristics
Sex, No. (%)
Male 77 (64.7) 73 (62.4)
Female 42 (35.3) 44 (37.6)
Age, median (range), y 72 (40-90) 71 (34-90)
Institution, No. (%)
Wakayama Medical University Hospital 108 (90.8) 109 (93.2)
Mie University Hospital 11 (9.2) 8 (6.8)
BMI, median (range) 22.4 (14.0-31.9) 21.9 (14.0-32.1)
ASA score, No. (%)
1 44 (37.0) 39 (33.3)
2 72 (60.5) 74 (63.2)
3 3 (2.5) 4 (3.4)
Comorbidity, No. (%)
Hypertension 62 (52.1) 53 (45.3)
Type 1 or 2 diabetes 28 (23.5) 20 (17.1)
Pulmonary 7 (5.9) 10 (8.5)
Cardiovascular 13 (10.9) 14 (12.0)
Renal 7 (5.9) 4 (3.4)
Hepatic 2 (1.7) 2 (1.7)
Cerebrovascular 16 (13.4) 6 (5.1)
History of abdominal surgery, No. (%) 27 (22.7) 32 (27.4)
Open cholecystectomy 4 (3.4) 2 (1.7)
Laparoscopic cholecystectomy 3 (2.5) 3 (2.6)
Appendectomy 14 (11.8) 18 (15.4)
Colorectal surgery 3 (2.5) 3 (2.6)
Gynecological surgery 7 (5.9) 8 (6.8)
Hepatectomy 0 1 (0.9)
Smoking history, Brinkman index, median (range) 60 (0-2500) 400 (0-4000)
Daily drinker, No. (%) 57 (47.9) 48 (41.0)
Tumor characteristics
Location, No. (%)
Upper third of the stomach 24 (20.2) 31 (26.5)
Middle third of the stomach 43 (36.1) 35 (29.9)
Lower third of the stomach 50 (42.0) 46 (39.3)
Whole stomach 2 (1.7) 5 (4.3)
Size, median (range), mm 32 (3-120) 35 (8-150)
Macroscopic type, No. (%)a
0 55 (46.2) 57 (48.7)
1 6 (5.0) 4 (3.4)
2 22 (18.5) 20 (17.1)
3 29 (24.4) 30 (25.6)
4 4 (3.4) 5 (4.3)
5 3 (2.5) 1 (0.9)
Histologic type, No. (%)a
Pap 1 (0.8) 1 (0.9)
Tub1 35 (29.4) 32 (27.4)
Tub2 34 (28.6) 28 (23.9)
Por 42 (35.3) 46 (39.3)
Sig 2 (1.7) 6 (5.1)
Muc 2 (1.7) 1 (0.9)
Others 3 (2.5) 3 (2.6)
pT stage, No. (%)b
T1a 23 (19.3) 25 (21.4)
T1b 40 (33.6) 43 (36.8)
T2 14 (11.8) 10 (8.5)
T3 26 (21.8) 25 (21.4)
T4a 15 (12.6) 11 (9.4)
T4b 1 (0.8) 3 (2.6)
pN stage, No. (%)b
N0 70 (58.8) 76 (65.0)
N1 24 (20.2) 19 (16.2)
N2 12 (10.1) 15 (12.8)
N3 13 (10.9) 7 (6.0)
pM stage, No. (%)b
M0 111 (93.3) 114 (97.4)
M1 8 (6.7) 3 (2.6)
p Stage, No. (%)b
IA 52 (43.7) 52 (44.4)
IB 19 (16.0) 16 (13.7)
IIA 12 (10.1) 18 (15.4)
IIB 9 (7.6) 13 (11.1)
IIIA 9 (7.6) 10 (8.5)
IIIB 5 (4.2) 2 (1.7)
IIIC 5 (4.2) 3 (2.6)
IV 8 (6.7) 3 (2.6)

Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); LG, laparoscopic gastrectomy; Muc, mucinous adenocarcinoma; Pap, papillary adenocarcinoma; Por, poorly differentiated adenocarcinoma; RG, robotic gastrectomy; Sig, signet-ring cell carcinoma; Tub1, well differentiated tubular adenocarcinoma; Tub2, moderately differentiated tubular adenocarcinoma.

a

Japanese Classification of Gastric Carcinoma.18

b

UICC 8th edition.17